The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging. Furthermore, the industry is undergoing structural transformation amid a period of M&A activity.
Key Takeaways
The State Street SPDR S&P Biotech ETF (XBI) gained 17.9% in the...